Ventilator-associated pneumonia in neurocritically ill patients: insights from the ENIO international prospective observational study.
Brain injury
Neurocritical care
Outcome
Pneumonia
Tracheobronchitis
Ventilator-associated pneumonia
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
30
03
2023
accepted:
21
05
2023
medline:
2
6
2023
pubmed:
1
6
2023
entrez:
31
5
2023
Statut:
epublish
Résumé
Acute brain injured (ABI) patients are at high risk of developing ventilator-associated pneumonia (VAP). However, incidence, risk factors and effects on outcome of VAP are not completely elucidated in this population. The primary aim of this study was to determine the incidence of VAP in a cohort of ABI patients. The secondary objectives included the identification of risk factors for development of VAP, and the impact of VAP on clinical outcomes. Clinical outcomes were defined as intensive care unit length of stay (ICU-LOS), duration of invasive mechanical ventilation (IMV), and ICU mortality. Pre-planned sub-analysis of the Extubation strategies in Neuro-Intensive care unit (ICU) patients and associations with Outcomes (ENIO) international multi-center prospective observational study. Patients with available data on VAP, who received at least 48 h of IMV and ICU-LOS ≥ 72 h were included. Out of 1512 patients included in the ENIO study, 1285 were eligible for this analysis. The prevalence of VAP was 39.5% (33.7 cases /1000 ventilator-days), with a high heterogeneity across countries and according to the type of brain injury. VAP was significantly more frequent in male patients, in those with smoke habits and when intraparenchymal probe (IP), external ventricular drain (EVD) or hypothermia (p < 0.001) were used. Independent risk factors for VAP occurrence were male gender, the use of IP, hypothermia, and the occurrence of tracheobronchitis during ICU stay. VAP was not an independent risk factor for ICU mortality (Hazard Ratio, HR = 0.71 95%CI 0.43-1.16, p = 0.168), but was independently associated with longer ICU stay (OR = 2.55 95%CI 2.01-3.23, p < 0.001). VAP is common in ABI patients. Male gender, IP and EVD insertion, tracheobronchitis, and the use of therapeutic hypothermia were significantly associated with VAP occurrence. VAP did not affect mortality but increased ICU-LOS.
Sections du résumé
BACKGROUND
BACKGROUND
Acute brain injured (ABI) patients are at high risk of developing ventilator-associated pneumonia (VAP). However, incidence, risk factors and effects on outcome of VAP are not completely elucidated in this population. The primary aim of this study was to determine the incidence of VAP in a cohort of ABI patients. The secondary objectives included the identification of risk factors for development of VAP, and the impact of VAP on clinical outcomes. Clinical outcomes were defined as intensive care unit length of stay (ICU-LOS), duration of invasive mechanical ventilation (IMV), and ICU mortality.
METHODS
METHODS
Pre-planned sub-analysis of the Extubation strategies in Neuro-Intensive care unit (ICU) patients and associations with Outcomes (ENIO) international multi-center prospective observational study. Patients with available data on VAP, who received at least 48 h of IMV and ICU-LOS ≥ 72 h were included.
RESULTS
RESULTS
Out of 1512 patients included in the ENIO study, 1285 were eligible for this analysis. The prevalence of VAP was 39.5% (33.7 cases /1000 ventilator-days), with a high heterogeneity across countries and according to the type of brain injury. VAP was significantly more frequent in male patients, in those with smoke habits and when intraparenchymal probe (IP), external ventricular drain (EVD) or hypothermia (p < 0.001) were used. Independent risk factors for VAP occurrence were male gender, the use of IP, hypothermia, and the occurrence of tracheobronchitis during ICU stay. VAP was not an independent risk factor for ICU mortality (Hazard Ratio, HR = 0.71 95%CI 0.43-1.16, p = 0.168), but was independently associated with longer ICU stay (OR = 2.55 95%CI 2.01-3.23, p < 0.001).
CONCLUSIONS
CONCLUSIONS
VAP is common in ABI patients. Male gender, IP and EVD insertion, tracheobronchitis, and the use of therapeutic hypothermia were significantly associated with VAP occurrence. VAP did not affect mortality but increased ICU-LOS.
Identifiants
pubmed: 37259054
doi: 10.1186/s12931-023-02456-9
pii: 10.1186/s12931-023-02456-9
pmc: PMC10234099
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
146Informations de copyright
© 2023. The Author(s).
Références
Front Physiol. 2021 Oct 18;12:711273
pubmed: 34733173
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Anesthesiology. 2004 Feb;100(2):234-9
pubmed: 14739794
Front Pharmacol. 2019 May 09;10:482
pubmed: 31143118
Intensive Care Med. 2020 May;46(5):888-906
pubmed: 32157357
N Engl J Med. 2015 Dec 17;373(25):2403-12
pubmed: 26444221
Cerebrovasc Dis. 2013;35(5):430-43
pubmed: 23735757
Intensive Care Med. 2022 Nov;48(11):1539-1550
pubmed: 36038713
Am J Infect Control. 2018 Jun;46(6):656-662
pubmed: 29395511
Neurocrit Care. 2019 Aug;31(1):196-210
pubmed: 29998427
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
Neurocrit Care. 2015 Aug;23(1):44-53
pubmed: 25634643
Neurocrit Care. 2020 Feb;32(1):272-285
pubmed: 31300956
Intensive Care Med. 2020 Dec;46(12):2397-2410
pubmed: 33175276
Ann Transl Med. 2020 Apr;8(7):503
pubmed: 32395547
Nat Rev Neurosci. 2005 Oct;6(10):775-86
pubmed: 16163382
JAMA. 1993 Oct 27;270(16):1965-70
pubmed: 8411554
Neurocrit Care. 2020 Oct;33(2):499-507
pubmed: 31974871
World Neurosurg. 2018 Jul;115:e393-e403
pubmed: 29678711
Acta Anaesthesiol Scand. 2013 Aug;57(7):848-54
pubmed: 23550742
J Neurosurg Anesthesiol. 2010 Jan;22(1):32-7
pubmed: 20027012
J Neurol. 2001 Nov;248(11):959-64
pubmed: 11757959
PLoS One. 2019 Jun 20;14(6):e0218372
pubmed: 31220122
JAMA Intern Med. 2013 Dec 9-23;173(22):2039-46
pubmed: 23999949
Best Pract Res Clin Anaesthesiol. 2021 Jul;35(2):207-220
pubmed: 34030805
Neurocrit Care. 2010 Apr;12(2):155-8
pubmed: 19806474
Crit Care Med. 2011 Jun;39(6):1482-92
pubmed: 21378554
Crit Care. 2021 Mar 19;25(1):111
pubmed: 33741052
J Trauma Acute Care Surg. 2014 Jul;77(1):161-5
pubmed: 24977772
Chest. 1988 Feb;93(2):318-24
pubmed: 3338299
Nat Rev Dis Primers. 2019 Mar 14;5(1):18
pubmed: 30872586
J Cereb Blood Flow Metab. 2017 Dec;37(12):3671-3682
pubmed: 27733675
JAMA. 2016 Dec 13;316(22):2427-2429
pubmed: 27835709
Eur J Clin Microbiol Infect Dis. 2014 May;33(5):823-30
pubmed: 24322991
Neurocrit Care. 2016 Oct;25(2):170-7
pubmed: 27350547
Chest. 2020 Dec;158(6):2292-2303
pubmed: 32634435
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Clin Microbiol Infect. 2021 Oct;27(10):1431-1438
pubmed: 34118423
Can Respir J. 2017;2017:7272080
pubmed: 29391844
Eur Respir J. 2018 Mar 29;51(3):
pubmed: 29545274